An experimental drug from GlaxoSmithKline Plc may one day give people a way to prevent HIV infection with an injection every three months instead of daily pills, raising the odds they’ll stick with the therapy.
The Obama administration boosted its pledge to the Global Fund to Fight AIDS, Tuberculosis & Malaria by 38 percent, to $4 billion, while urging changes to make the organization more efficient and more accountable.
The largest and most advanced study under way of a vaccine to prevent HIV infection was stopped by U.S. government researchers after an interim look at the data showed it was unlikely to help recipients.
A vaginal gel containing Gilead Sciences Inc. ’s AIDS drug Viread cut HIV infections by as much as 54 percent in a trial in South Africa, the first time such a product has protected women after six previous gels failed.
Millions of HIV infections could be averted by treating patients earlier than current guidelines recommend, after a study showed giving pills to patients as soon as they’re diagnosed can prevent them infecting others.
Doctors can give the HIV medicine Truvada as a preventative to healthy heterosexuals at high risk of the virus and should treat gonorrhea differently to hold off a drug-resistant form growing outside the country, U.S. officials said.
Drugs made by Gilead Sciences Inc. that can prevent healthy adults from getting HIV didn’t reduce infections in African women because of lack of adherence to treatment, raising questions about the medicines’ usefulness in stopping the spread of AIDS.